Multiple Myeloma

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

By

Christina Bennett, MS

Publish Date January 13, 2021

Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.

Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma

By

Christina Bennett, MS

Publish Date January 13, 2021

Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.

Pegylated Interferon Controlled Extreme Thrombocytosis, Well-Tolerated in Younger Patients With MPN

By

Jessica Nye, PhD

Publish Date January 12, 2021

A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.

Effects of Daratumumab on Patient-Reported Outcomes, HRQOL in Newly Diagnosed Multiple Myeloma

By

Jonathan Goodman, MPhil

Publish Date January 7, 2021

Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.

Laboratory Markers Found to Correlate With Symptom Burden in Relapsed/Refractory Multiple Myeloma

By

Vicki Moore, PhD

Publish Date January 5, 2021

Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.